Cellular Biomedicine Group, Inc.
CBMG
CBMG was delisted on the 19th of February, 2021.
67 hedge funds and large institutions have $80M invested in Cellular Biomedicine Group, Inc. in 2020 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 28 increasing their positions, 15 reducing their positions, and 12 closing their positions.
87% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 15
2% more capital invested
Capital invested by funds: $78.5M → $80M (+$1.55M)
8% less funds holding
Funds holding: 73 → 67 (-6)
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
68% less call options, than puts
Call options by funds: $529K | Put options by funds: $1.64M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AGM
Alpine Global Management
New York
|
+$1.73M |
| 2 |
Morgan Stanley
New York
|
+$1.51M |
| 3 |
JP Morgan Chase
New York
|
+$1.35M |
| 4 |
GCIA
Gabelli & Co Investment Advisers
Rye,
New York
|
+$1.2M |
| 5 |
GF
Gabelli Funds
Rye,
New York
|
+$1.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WIC
Water Island Capital
New York
|
-$2.44M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$1.3M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$858K |
| 4 |
MAM
Martingale Asset Management
Boston,
Massachusetts
|
-$711K |
| 5 |
Man Group
London,
United Kingdom
|
-$649K |
CBMG Hedge Fund Activity: Q4 2020 in Review
67 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q4 2020, worth a combined $80M — up 2% from $78.5M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of CBMG and 6 opened new positions — a net loss of 6 holders — while 15 trimmed existing stakes and 28 added.
The largest buyer was Alpine Global Management, adding an estimated $1.73M. The largest seller was Water Island Capital, exiting entirely with an estimated $2.44M sold.
- 67 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q4 2020, down from 73 in Q3 2020.
- Funds reported $80M of Cellular Biomedicine Group, Inc. stock for Q4 2020, up 2% quarter-over-quarter.
- 6 funds opened new Cellular Biomedicine Group, Inc. positions in Q4 2020 and 12 closed out, a net change of -6 holders.
- The largest Cellular Biomedicine Group, Inc. buyer in Q4 2020 was Alpine Global Management, an estimated $1.73M added.
- The largest Cellular Biomedicine Group, Inc. seller in Q4 2020 was Water Island Capital, an estimated $2.44M sold.
Based on aggregated 13F filings for Q4 2020.